Lawsuits against large pharmaceutical companies alleging the use of inaccurate patent listings to deter competitors from creating generic alternatives to prescription drugs continue to grow.
Teva Pharmaceutical Industries, for instance, was hit with two antitrust class actions in Massachusetts federal court.
